DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme
- Conference Call with Live Webcast Today at 5:30 p.m. CDT / 6:30 p.m. EDT-
VANCOUVER, British Columbia and MENLO PARK, Calif., June 1, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced that it will be hosting a business update conference call and live webcast today, June 1, 2015, at 5:30 p.m. CDT (6:30 p.m. EDT).
Management will discuss data from its Phase I/II study of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), entitled, "Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma," (abstract No.2023) presented today at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
DelMar's data will be presented in the Central Nervous System Tumor Session, which is being held between 1:15 p.m. and 4:45 p.m. CDT at the McCormick Place Convention Center in Chicago, IL.
Following the presentation, the Company will host a conference call at 5:30 p.m. CDT (6:30 p.m. EDT) to discuss the data. Jeffrey Bacha, DelMar's president & CEO will be joined on the call by Dr. Dennis Brown, the Company's co-founder and Chief Scientific Officer, Dr. Richard Schwartz, the Company's Chief Medical Officer and Dr. Kent Shih, a principal investigator in the Company's clinical trial.
For both "listen-only" participants and those who wish to take part in the question and answer portion of the call, the conference telephone numbers are toll-free (866) 394-9399 or international (920) 663-6223. Please reference Conference ID 57681055.
A link to the webcast and slides will be available on the IR Calendar of the Investors section of the Company's website at www.delmarpharma.com, and will be archived for 30 days. Webcast participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software.
VAL-083 is a "first-in-class", small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institutes, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.
As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).
DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA). Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. (ClinicalTrials.gov Identifier NCT01478178).
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: firstname.lastname@example.org / (604) 629-5989. Follow us on Twitter @DelMarPharma or Facebook.com/delmarpharma. Investor Relations Counsel: Amato & Partners LLC.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-host-investor-conference-call-on-june-1-2015-to-discuss-new-val-083-phase-iii-clinical-data-in-patients-with-refractory-glioblastoma-multiforme-300091431.html
SOURCE DelMar Pharmaceuticals, Inc.
Released June 1, 2015